CPV-104

Phase 1Small molecule

Eeleva GmbH

CPV-104 is one of 2 small molecule programs targeting C3 Glomerulopathy (C3G). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

C3 Glomerulopathy (C3G)Recruiting

C3 Glomerulopathy (C3G)Phase 1

Recruiting

Competition

Competitive Landscape

1 competitor in C3 Glomerulopathy (C3G)

#DrugCompanyPhaseTrials

Empaveli

Apellis Pharmaceuticals

Approved

1 2

CPV-104

Eeleva GmbH

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

C3 Glomerulopathy (C3G)

NCT07483827

Clinical

Trials by Indication[1]

C3 Glomerulopathy (C3G)1 trial

A Phase 1 First-in-Human Clinical Trial in Healthy Participants and Patients With C3-Glomerulopathy to Assess Safety, Tolerability, and Pharmacokinetics of CPV-104

Recruiting·Eeleva GmbH·Phase 1·NCT07483827·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CPV-104. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CPV-104 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CPV-104. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — eleva GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eeleva GmbH

CPV-104

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

C3 Glomerulopathy (C3G)1 trial

References

Drug Info

Quick Facts

Related News